Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report released on Tuesday. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

NYSE:BTX opened at $7.87 on Tuesday. The stock’s 50 day moving average price is $0.49 and its 200 day moving average price is $0.93. Brooklyn ImmunoTherapeutics has a 52 week low of $0.17 and a 52 week high of $10.10. The company has a market capitalization of $462.67 million, a P/E ratio of -3.46 and a beta of 4.61.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.